The biopharmaceutical industry is crucial in delivering life-saving medications, vaccines, and therapies to patients worldwide. However, recent challenges—such as the COVID-19 pandemic and geopolitical events like the war in Ukraine—have highlighted the necessity for the outbound supply chain to transform into a more agile, robust, and cost-effective system that caters to the needs of patients.
A well-functioning outbound biopharmaceutical supply chain is critically important to industry as delays, shortages, and inefficiencies cause disruption to the availability of essential medications and compromise patient care. While other industry supply chains have successfully embraced digitalization, agility and customer-centricity, the pharmaceutical supply chain has lagged.
“As modalities become more complex, we must develop strategies to manage new handling characteristics (e.g., deep frozen, cytotoxic ADCs, autologous treatment, etc.) while simultaneously abiding by all regulations and minimizing our environmental impacts,” said Rich Whiteman, Associate Director of Clinical Supply Chain Strategy & Innovation at Janssen. “This demands an evolved clinical supply chain which is more nimble, adaptable, and sustainable.”
To drive change within industry, it is now more important than ever to collaborate, identify the key challenges, and understand what a future supply chain would require to be successful for the ultimate benefit of patients worldwide.
This is why we have published A visionary Strategic Framework for future patient-centric outbound biopharmaceutical supply chains.
The Framework is a reference for the biopharmaceutical industry, enabling organizations to align with industry trends, reassess their priorities, and plan future developments. Our Supply Chain to Patient Phorum will use the Framework objectives to evaluate its program and ensure alignment with industry goals, fostering focused collaboration.
The Framework focuses on five strategic objectives:
- Data-driven decision-making: fully digital integrated supply chain enabled by accurate real-time information
- Uninterrupted, cost-effective, agile supply chain: ensuring continuity of supply in an adaptable and cost-effective manner
- Sustainable and responsible: sustainable supply chain with minimized impact on the planet
- Dynamic and skilled workforce: diverse workforce supported by ongoing training and development opportunities
- Drive innovation through collaboration: engaging with regulators, healthcare and patients to drive innovation and industry collaboration.
“The Supply Chain to Patient Strategic Framework aims to enhance the efficiency and visibility of healthcare supply chains,” said Craig Embleton, Executive Director of Global Logistics CSC, Bristol Myers Squibb.” This will ensure that essential medical products reach patients in a timely manner, ultimately improving patient care and outcomes.”
The Framework targets the outbound biopharmaceutical supply chain. Established organizations can align their existing frameworks with industry standards while emerging ones can adopt or directly customize the Framework.
It can be used by the leaders and managers of a range of organizations in industry—including biomanufacturers and cell and gene therapy companies and partners such as logistic organizations, technology providers, clinical research organizations, and contract development and manufacturing organizations. These can gain insights into biopharmaceutical supply chain needs and align their offerings accordingly.
By having a framework that is open and transparent about industry goals, organizations can communicate their aligned direction and intentions to all associated suppliers and partners, which in turn will allow understanding and promote collaboration with suppliers and key stakeholders. Within organizations, the Framework can be used by leaders in different departments, such as global supply chain, global strategic sourcing, business and operational excellence, product development, product management and procurement.
This Framework is the first deliverable of a multi-part project and will be accompanied by a maturity model that will be aligned with the strategic objectives in the Framework. The maturity model will allow biopharmaceutical organizations to assess their maturity level in each area and enable industry benchmarking.
For more information, download the paper here and contact Scott Clayton, Account Manager, at firstname.lastname@example.org